SpaceX vs Tilray Brands Inc — how do they compare? SpaceX trades at $147.05 (market cap $2.02T), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: SpaceX is far larger — about 3414.5× Tilray Brands Inc's market cap, and SpaceX is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| SPCX | TLRY | |
|---|---|---|
Market Cap | $2.02T | $591.60M |
Sector | Technology | Health |
52-Week High | $202.09 | $21.00 |
52-Week Low | $108.27 | $3.88 |
Enterprise Value | $1.96T | $758.73M |
Signals from Pluang's Aura AI — not financial advice
SPCX trades at $153.47, up 3.73% today, with strong analyst support (90% buy ratings) and a $227.22 consensus price target suggesting 48% upside. Despite negative profitability metrics, the company shows robust revenue growth and significant cash flow generation. Technical indicators show a bullish trend with key support at $147 and resistance at $157. Recent news highlights insider share unlocks creating temporary selling pressure but strong institutional interest.
The outlook remains positive given SpaceX's innovation pipeline and market leadership, though investors face risks from high valuation multiples, ongoing losses, and competitive pressures. The stock's premium valuation requires continued execution on growth targets to justify current levels.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →